Molecular Pharmacology Program
The David Scheinberg Lab
The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials and a vaccine to WT1 about to enter Phase III trials. Read full article in Science. A WT1 vaccine is also in late stage national trials (Blood, 2010).
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013).
Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127(7):2705-18. Epub 2017/06/20. doi: 10.1172/jci92335. PubMed. PMCID: PMC5490756.
David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK
- Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
- MD, PhD, Johns Hopkins University School of Medicine
- Ph.D, 1990, Immunology, Hyogo College of Medicine, Japan
- MD, 1982, Medicine, Medical School of Inner Mongolia
- Molecular Pharmacology Program
- Department of Medicine
- Center for Experimental Therapeutics
- Center for Cell Engineering
- Geoffrey Beene Cancer Research Center
- Center for Molecular Imaging & Nanotechnology
- Tri-Institutional PhD Program in Chemical Biology
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David A. Scheinberg discloses the following relationships and financial interests:
KLUS Pharma, Inc
Provision of Services
Lantheus Medical Imaging, Inc.
Ownership / Equity Interests
Provision of Services
Ownership / Equity Interests; Provision of Services
Progenics Pharmaceuticals, Inc.
Provision of Services (uncompensated)
Sapience Therapeutics, Inc.
Fiduciary Role/Position; Ownership / Equity Interests
Sellas Life Science Group
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.